244 related articles for article (PubMed ID: 19887552)
1. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
2. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
3. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
4. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.
Rajabi H; Ahmad R; Jin C; Joshi MD; Guha M; Alam M; Kharbanda S; Kufe D
Prostate; 2012 Nov; 72(15):1659-68. PubMed ID: 22473899
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells.
Rajabi H; Joshi MD; Jin C; Ahmad R; Kufe D
Prostate; 2011 Sep; 71(12):1299-308. PubMed ID: 21308711
[TBL] [Abstract][Full Text] [Related]
6. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.
Raina D; Ahmad R; Joshi MD; Yin L; Wu Z; Kawano T; Vasir B; Avigan D; Kharbanda S; Kufe D
Cancer Res; 2009 Jun; 69(12):5133-41. PubMed ID: 19491255
[TBL] [Abstract][Full Text] [Related]
7. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
Alam M; Rajabi H; Ahmad R; Jin C; Kufe D
Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886
[TBL] [Abstract][Full Text] [Related]
8. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
Premaratne P; Welén K; Damber JE; Hansson GC; Bäckström M
Tumour Biol; 2011 Feb; 32(1):203-13. PubMed ID: 20872286
[TBL] [Abstract][Full Text] [Related]
9. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
[TBL] [Abstract][Full Text] [Related]
10. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.
Hasegawa M; Sinha RK; Kumar M; Alam M; Yin L; Raina D; Kharbanda A; Panchamoorthy G; Gupta D; Singh H; Kharbanda S; Kufe D
Clin Cancer Res; 2015 May; 21(10):2338-47. PubMed ID: 25712682
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L; Kosugi M; Kufe D
Blood; 2012 Jan; 119(3):810-6. PubMed ID: 22117045
[TBL] [Abstract][Full Text] [Related]
12. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.
Yin L; Ahmad R; Kosugi M; Kufe T; Vasir B; Avigan D; Kharbanda S; Kufe D
Mol Pharmacol; 2010 Aug; 78(2):166-74. PubMed ID: 20444960
[TBL] [Abstract][Full Text] [Related]
13. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
14. Phenoxodiol inhibits growth of metastatic prostate cancer cells.
Aguero MF; Venero M; Brown DM; Smulson ME; Espinoza LA
Prostate; 2010 Aug; 70(11):1211-21. PubMed ID: 20564423
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma.
GongSun X; Zhao Y; Jiang B; Xin Z; Shi M; Song L; Qin Q; Wang Q; Liu X
J Cell Physiol; 2019 Jul; 234(7):12019-12028. PubMed ID: 30523643
[TBL] [Abstract][Full Text] [Related]
16. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.
Yin L; Ahmad R; Kosugi M; Kawano T; Avigan D; Stone R; Kharbanda S; Kufe D
Cancer Biol Ther; 2010 Sep; 10(5):483-91. PubMed ID: 20592495
[TBL] [Abstract][Full Text] [Related]
17. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
18. Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.
Chen M; Zhou B; Zhong P; Rajamanickam V; Dai X; Karvannan K; Zhou H; Zhang X; Liang G
Prostate; 2017 Apr; 77(5):489-504. PubMed ID: 27990666
[TBL] [Abstract][Full Text] [Related]
19. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
